关于吡格列酮能减少大血管事件的证据在多大程度上支持了研究人员的说法？
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
作者信息
Freemantle Nick
机构信息
University of Birmingham, Birmingham B15 2TT.
出版信息
BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836.
Abstract
Recent claims that pioglitazone prevents macrovascular events are based on a secondary outcome measure. But ignoring the primary outcome is statistically unsound
摘要
最近有关吡格列酮可预防大血管事件的说法是基于次要结局指标。但忽视主要结局在统计学上是不合理的。
相似文献
1
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836.
2
Glitazones in type 2 diabetes: an update.
Drug Ther Bull. 2008 Apr;46(4):25-9. doi: 10.1136/dtb.2008.03.0008.
3
[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
Internist (Berl). 2007 Jan;48(1):89-90; discussion 90-1. doi: 10.1007/s00108-006-1777-6.
4
[How does the PROactive Study change therapy of diabetes?].
MMW Fortschr Med. 2005 Oct 13;147(41):6.
5
[Prospective pioglitazone clinical trial in macrovascular events].
Nihon Rinsho. 2012 May;70 Suppl 3:301-8.
6
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
MMW Fortschr Med. 2003 Sep 11;145(37):65.
7
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Trends Cardiovasc Med. 2009 Apr;19(3):94-9. doi: 10.1016/j.tcm.2009.06.002.
8
Intensive glucose lowering treatment in type 2 diabetes.
BMJ. 2011 Jul 26;343:d4243. doi: 10.1136/bmj.d4243.
9
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
J Diabetes. 2010 Sep;2(3):212-20. doi: 10.1111/j.1753-0407.2010.00082.x.
10
[Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
MMW Fortschr Med. 2003 Oct 9;145(41):47.
引用本文的文献
1
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study.
Clin Trials. 2012 Feb;9(1):113-24. doi: 10.1177/1740774511432726.
2
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4. Epub 2011 Oct 29.
3
Overviews of pathogen emergence: which pathogens emerge, when and why?
Curr Top Microbiol Immunol. 2007;315:85-111. doi: 10.1007/978-3-540-70962-6_5.
4
Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology.
Diabetologia. 2007 Aug;50(8):1576-86. doi: 10.1007/s00125-007-0711-3. Epub 2007 Jun 26.
5
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
BMJ. 2005 Dec 17;331(7530):1474-5. doi: 10.1136/bmj.331.7530.1474-c.
6
ASCOT: a tale of two treatment regimens: odds are that it's hype.
BMJ. 2005 Oct 29;331(7523):1022-3. doi: 10.1136/bmj.331.7523.1022-b.
本文引用的文献
1
Composite outcomes in randomized trials: greater precision but with greater uncertainty?
JAMA. 2003 May 21;289(19):2554-9. doi: 10.1001/jama.289.19.2554.
2
Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?
BMJ. 2001 Apr 21;322(7292):989-91. doi: 10.1136/bmj.322.7292.989.
3
Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.
Control Clin Trials. 1999 Feb;20(1):16-39. doi: 10.1016/s0197-2456(98)00054-3.
Zotero 插件